Literature DB >> 19329778

Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.

Claudio G Brunstein1, John E Wagner, Daniel J Weisdorf, Sarah Cooley, Harriet Noreen, Juliet N Barker, Todd DeFor, Michael R Verneris, Bruce R Blazar, Jeffrey S Miller.   

Abstract

We examined the clinical impact of killer-immunoglobulin receptor-ligand (KIR-L) mismatch in 257 recipients of single (n = 91) or double (n = 166) unit umbilical cord blood (UCB) grafts after myeloablative (n = 155) or reduced intensity (n = 102) conditioning regimens. Analyses of double unit grafts considered the KIR-L match status of the dominant engrafting unit. After myeloablative conditioning, KIR-L mismatch had no effect on grade III-IV acute graft-versus-host disease (GVHD), transplantation-related mortality (TRM), relapse, and survival. In contrast, after reduced intensity conditioning, KIR-L mismatch between the engrafted unit and the recipient resulted in significantly higher rates of grade III-IV acute GVHD (42% [CI, 27-59] vs 13% [CI, 5-21], P < .01) and TRM (27% [CI, 12%-42%] vs 12% [CI, 5%-19%], P = .03) with inferior survival (32% [CI, 15%-59%] vs 52% [CI, 47%-67%], P = .03). Multivariate analysis identified KIR-L mismatch as the only predictive factor associated with the development of grade III-IV acute GVHD (RR, 1.8 [CI, 1.1-2.9]; P = .02) and demonstrated a significant association between KIR-L mismatch and increased risk of death (RR, 1.8; 95% CI, 1.0-3.1; P = .05). Our results do not support the selection of UCB units based on KIR-L status and suggest that KIR-L mismatching should be avoided in reduced intensity UCB transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329778      PMCID: PMC2689057          DOI: 10.1182/blood-2008-12-197467

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation.

Authors:  B G Thomson; K A Robertson; D Gowan; D Heilman; H E Broxmeyer; D Emanuel; P Kotylo; Z Brahmi; F O Smith
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.

Authors:  Hongbo Wang; Bartosz Grzywacz; David Sukovich; Valarie McCullar; Qing Cao; Alisa B Lee; Bruce R Blazar; David N Cornfield; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

3.  Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells.

Authors:  J S Miller; V McCullar; M Punzel; I R Lemischka; K A Moore
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

4.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

5.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Authors:  Loredana Ruggeri; Antonella Mancusi; Marusca Capanni; Elena Urbani; Alessandra Carotti; Teresa Aloisi; Martin Stern; Daniela Pende; Katia Perruccio; Emanuela Burchielli; Fabiana Topini; Erika Bianchi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

6.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

Review 7.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.

Authors:  Sherif S Farag; Todd A Fehniger; Loredana Ruggeri; Andrea Velardi; Michael A Caligiuri
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.

Authors:  Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

Review 9.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  52 in total

1.  Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Authors:  D-F Chen; V K Prasad; G Broadwater; N L Reinsmoen; A DeOliveira; A Clark; K M Sullivan; J P Chute; M E Horwitz; C Gasparetto; G D Long; Y Yang; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

Review 2.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

3.  Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood.

Authors:  Nicolas Guillaume; Pascale Loiseau; Katia Gagne; Hélène Moins Teissserenc; Jean-Michel Cayuela; Guylaine Henry; Marie Robin; Régis Peffault de Latour; Eliane Gluckman; Gérard Socié; Christelle Retiere; Nicolas Dulphy; Antoine Toubert
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

Review 4.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 6.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

Review 7.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

Review 8.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

9.  Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies.

Authors:  Jon J van Rood; Cladd E Stevens; Jacqueline Smits; Carmelita Carrier; Carol Carpenter; Andromachi Scaradavou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

Review 10.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.